# Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

> **NCT00843713** · PHASE4 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 56 (actual)

## Conditions studied

- HIV Infection
- Inflammation
- Cardiovascular Disease
- HIV Infections

## Interventions

- **DRUG:** raltegravir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00843713
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2013-11
- **Final completion:** 2014-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00843713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00843713, "Effect of Raltegravir on Endothelial Function in HIV-Infected Patients". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00843713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*